Slynd - (4 mg ; Tablets)

Generic Name	Drospirenone	Innovator	Exeltis
Dosage	4 mg ; Tablets	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	SLYND is a progestin indicated for use by females of reproductive potential to prevent pregnancy.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** / ***	*** **, ****	********* ******* / ********* ******* / ********* **** ** **	********* ********	** *** **, ****
********	** \ **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events